{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:01:07Z","timestamp":1793912467876,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Combination pharmacotherapy with tamsulosin plus tadalafil could be a superior strategy compared to conventional monotherapy with tamsulosin in patients with Benign prostatic obstruction (BPO) with or without erectile dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A comprehensive search was conducted across PubMed, the Cochrane Library, and Embase to identify studies assessing the efficacy and safety of combination therapy compared with monotherapy in patients with BPO with or without erectile dysfunction. A random effects meta-analysis was performed with R version 4.4.1 using the 'meta' package.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included eleven RCTs, with a combined total of 940 patients. Our analysis demonstrated that the combination therapy is associated with a greater reduction in overall IPSS (MD\u2009= \u2212\u20092.78, 95% CI\u2009\u2212\u20093.97 to\u2009\u2212\u20091.59; P\u2009&lt;\u20090.01), IIEF (MD\u2009=\u20092.98, 95% CI 1.64 to 4.33; P\u2009&lt;\u20090.01), QoL score (MD\u2009= \u2212\u20090.58, 95% CI\u2009\u2212\u20090.86 to\u2009\u2212\u20090.30; P\u2009&lt;\u20090.01), PVR (MD\u2009= \u2212\u20099.34, 95% CI\u2009=\u2009-15.52 to\u2009\u2212\u20093.16; P\u2009&lt;\u20090.01) and a significant improvement in Qmax (MD\u2009=\u20091.04, 95% CI 0.43 to 1.64; P\u2009&lt;\u20090.01) as compared to tamsulosin alone. However, combination therapy resulted in a higher incidence of pain (OR\u2009=\u20095.66, 95% CI 2.56 to 12.52; P\u2009&lt;\u20090.01) and other adverse events (OR\u2009=\u20092.97, 95% CI 1.60 to 5.49; P\u2009&lt;\u20090.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combination therapy with tamsulosin and tadalafil demonstrated superior efficacy over tamsulosin monotherapy in reducing LUTS, improving quality of life, and enhancing erectile function. However, it was associated with a higher incidence of adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05662-w","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T09:02:53Z","timestamp":1746954173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tamsulosin plus Tadalafil compared with Tamsulosin alone for benign prostate hyperplasia in patients with or without erectile dysfunction: a meta-analysis and meta-regression of randomized controlled trials"],"prefix":"10.1007","volume":"43","author":[{"given":"Tallal Mushtaq","family":"Hashmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohma","family":"Zia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadiah","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momina","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valencia","family":"Rumampouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momina Aslam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushood","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-685X","authenticated-orcid":false,"given":"Javed","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"issue":"1","key":"5662_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118\u2013140","journal-title":"Eur Urol"},{"issue":"11","key":"5662_CR2","first-page":"741","volume":"18","author":"Y Homma","year":"2011","unstructured":"Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A, Yamanishi T et al (2011) Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol Off J Jpn Urol Assoc 18(11):741\u2013756","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"6","key":"5662_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306\u20131314 (discussion 1314-1315)","journal-title":"Eur Urol"},{"issue":"2","key":"5662_CR4","first-page":"193","volume":"20","author":"O Yokoyama","year":"2013","unstructured":"Yokoyama O, Yoshida M, Kim SC, Wang CJ, Imaoka T, Morisaki Y et al (2013) Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol Off J Jpn Urol Assoc 20(2):193\u2013201","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"4","key":"5662_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK et al (2021) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Part I-initial work-up and medical management. J Urol 206(4):806\u2013817","journal-title":"J Urol"},{"issue":"Suppl 1","key":"5662_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bju.15098","volume":"126","author":"A Morton","year":"2020","unstructured":"Morton A, Williams M, Perera M, Teloken PE, Donato P, Ranasinghe S et al (2020) Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. BJU Int 126(Suppl 1):18\u201326","journal-title":"BJU Int"},{"issue":"2","key":"5662_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/nau.24285","volume":"39","author":"T Yamanishi","year":"2020","unstructured":"Yamanishi T, Kaga K, Sakata K, Yokoyama T, Kageyama S, Fuse M et al (2020) A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn 39(2):804\u2013812","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"5662_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1743-6109.2008.01138.x","volume":"6","author":"S Oger","year":"2009","unstructured":"Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, Denoux Y et al (2009) Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 6(3):836\u2013847","journal-title":"J Sex Med"},{"issue":"4","key":"5662_CR9","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.juro.2008.06.079","volume":"180","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180(4):1228\u20131234","journal-title":"J Urol"},{"issue":"2","key":"5662_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00002512-200219020-00004","volume":"19","author":"CJ Dunn","year":"2002","unstructured":"Dunn CJ, Matheson A, Faulds DM (2002) Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 19(2):135\u2013161","journal-title":"Drugs Aging"},{"issue":"1","key":"5662_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","volume":"70","author":"M Gacci","year":"2016","unstructured":"Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M et al (2016) Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 70(1):124\u2013133","journal-title":"Eur Urol"},{"issue":"3","key":"5662_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/nau.20999","volume":"30","author":"KE Andersson","year":"2011","unstructured":"Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG et al (2011) Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 30(3):292\u2013301","journal-title":"Neurourol Urodyn"},{"key":"5662_CR13","doi-asserted-by":"crossref","unstructured":"Sebastianelli A, Spatafora P, Morselli S, Vignozzi L, Serni S, McVary KT, et al. Tadalafil alone or in combination with tamsulosin for the management for LUTS\/BPH and ED. Curr Urol Rep 2020; 21(12): 56","DOI":"10.1007\/s11934-020-01009-7"},{"issue":"1","key":"5662_CR14","doi-asserted-by":"publisher","first-page":"155798832311550","DOI":"10.1177\/15579883231155096","volume":"17","author":"R Zhou","year":"2023","unstructured":"Zhou R, Che X, Zhou Z, Ma Y (2023) A systematic review and meta-analysis of the efficacy and safety of tamsulosin plus tadalafil compared with tamsulosin alone in treating males with lower urinary tract symptoms secondary to benign prostrate hyperplasia. Am J Mens Health 17(1):15579883231155096","journal-title":"Am J Mens Health"},{"issue":"2","key":"5662_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000535606","volume":"108","author":"J Liu","year":"2024","unstructured":"Liu J, Zhou W, Zhang P, Zhang W, Chang C, Fu G (2024) Comparison of monotherapies and combination therapy of tamsulosin and tadalafil for treating lower urinary tract symptoms caused by benign prostatic hyperplasia with or without erectile dysfunction: a meta-analysis. Urol Int 108(2):89\u201399","journal-title":"Urol Int"},{"key":"5662_CR16","unstructured":"Higgins, JPT. Cochrane handbook for systematic reviews of interventions, The Cochrane Collaboration. http:\/\/www.cochrane-handbook.org."},{"issue":"372","key":"5662_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29(372):n71","journal-title":"BMJ"},{"issue":"6","key":"5662_CR18","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/TCRM.S3336","volume":"4","author":"RM Coward","year":"2008","unstructured":"Coward RM, Carson CC (2008) Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag 4(6):1315\u20131330","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"5662_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0022-5347(17)40572-6","volume":"141","author":"ML Stoller","year":"1989","unstructured":"Stoller ML, Millard RJ (1989) The accuracy of a catheterized residual urine. J Urol 141(1):15\u201316","journal-title":"J Urol"},{"issue":"1","key":"5662_CR20","first-page":"17","volume":"13","author":"JL Ruud Bosch","year":"1995","unstructured":"Ruud Bosch JL (1995) Postvoid residual urine in the evaluation of men with benign prostatic hyperplasia. World J Urol 13(1):17\u201320","journal-title":"World J Urol"},{"issue":"5","key":"5662_CR21","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ, O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The american urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol 148(5):1549\u20131557","journal-title":"J Urol"},{"issue":"3","key":"5662_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TLJ, Wirth M, Koldewijn E, Fern\u00e1ndez FE (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59(3):342\u2013352","journal-title":"Eur Urol"},{"issue":"5","key":"5662_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.eururo.2011.07.053","volume":"60","author":"RC Rosen","year":"2011","unstructured":"Rosen RC, Allen KR, Ni X, Araujo AB (2011) Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 60(5):1010\u20131016","journal-title":"Eur Urol"},{"key":"5662_CR24","doi-asserted-by":"crossref","unstructured":"Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J, International consultation on new developments in prostate cancer and prostate diseases. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2013;189(1 Suppl):S93\u2013101.","DOI":"10.1016\/j.juro.2012.11.021"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05662-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05662-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05662-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:54:55Z","timestamp":1767966895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05662-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5662"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05662-w","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval was required for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No consent was needed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}],"article-number":"291"}}